Resultats de la cerca - Hong Zebger‐Gong
- Mostrar 1 - 7 resultats de 7
-
1
-
2
EPO and α-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney per Hong Zebger‐Gong, Weidong Wang, Tae‐Hwan Kwon, Thomas E. N. Jonassen, Chunling Li, Troels Ring, Jørgen Frøkiær, Søren Nielsen
Publicat 2004Artigo -
3
Uremia-related vascular calcification: More than apatite deposition per Steven Verberckmoes, Veerle P. Persy, Geert J. Behets, Ellen Neven, Ann-Sophie Hufkens, Hong Zebger‐Gong, Dominik N. Müller, Dieter Haffner, Uwe Querfeld, Sylvain Bohic, Marc E. De Broe, Patrick C. D’Haese
Publicat 2006Artigo -
4
Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study per Michela Casanova, Francisco Bautista, Quentin Campbell-Hewson, Guy Makin, Lynley V. Marshall, Arnauld Verschuur, Adela Cañete, Nadège Corradini, Bart A. Ploeger, Barbara J. Brennan, Udo Mueller, Hong Zebger‐Gong, John W. Chung, Birgit Geoerger
Publicat 2023Artigo -
5
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lun... per Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, Alexander I. Spira, Edward B. Garon, Satoru Kitazono, Melissa L. Johnson, Funda Meric‐Bernstam, Anthony W. Tolcher, Noboru Yamamoto, Jon Greenberg, Yui Kawasaki, Hong Zebger‐Gong, Fumiaki Kobayashi, Penny Phillips, Aaron Lisberg, Rebecca S. Heist
Publicat 2023Artigo -
6
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study per Aditya Bardia, Ian E. Krop, Takahiro Kogawa, Dejan Juric, Anthony W. Tolcher, Erika Hamilton, Toru Mukohara, Aaron Lisberg, Toshio Shimizu, Alexander I. Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P. Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger‐Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric‐Bernstam
Publicat 2024Artigo -
7
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study per Marwan Fakih, Kanwal Pratap Singh Raghav, David Chang, Tim Larson, Allen Lee Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Rachel Tam, David R. D’Adamo, Neelesh Sharma, Barbara J. Brennan, Ying A. Wang, Sabine Coppieters, Hong Zebger‐Gong, Anke Weispfenning, Henrik Seidel, Bart A. Ploeger, Udo Mueller, Carolina S.V. Oliveira, Andrew Scott Paulson
Publicat 2023Artigo
Eines de cerca:
Matèries relacionades
Internal medicine
Medicine
Adverse effect
Chemotherapy
Cancer
Gastroenterology
Progressive disease
Tolerability
Chemistry
Colorectal cancer
Environmental health
Oncology
Phases of clinical research
Population
Regorafenib
Surgery
Apatite
Aquaporin 2
Asthma
Astrobiology
Biology
Breast cancer
Calcification
Calcinosis
Clinical endpoint
Clinical trial
Cotransporter
Cyclophosphamide
Deposition (geology)
Diffusing capacity